Across TCGA pan-cancer cohorts, FAM228A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM228A data layer compared with 24 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher FAM228A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM228A expression acts as an unfavorable survival marker.

PRAD and BRCA are the cancer types where FAM228A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BRCA	OS	Median	All	0.842	0.963	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: FAM228A tumor-vs-normal RNA expression · all FAM228A data types